FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3013765366> ?p ?o ?g. }

• W3013765366 endingPage "07" @default.
• W3013765366 startingPage "OT2" @default.
• W3013765366 abstract "Abstract Background: In this year, anti-programmed death-ligand 1 (PD-L1) antibody has been approved for PD-L1-positive metastatic triple-negative breast cancer by the U.S. Food and Drug Administration. The synergistic effect of the combination of anti-PD-L1 antibody, CDK4/6 inhibitor and endocrine therapy (ET) has been anticipated based on various preclinical data. A Phase Ib study (JPCE, NCT02779751) of abemaciclib plus pembrolizumab demonstrated manageable safety and promising anti-tumor activity in patients with HR-positive (HR+), HER2-negative (HER2-) metastatic breast cancer (MBC). Therefore, we initiated this investigator-initiated trial to evaluate the efficacy and safety of the combination of nivolumab, abemaciclib and ET (letrozole [LET] or fulvestrant [FUL]) as a first or second-line treatment in patients with HR+, HER2- MBC. Trial Design: This is a multicenter, multi-cohort, nonrandomized, open-label Phase II study to evaluate the efficacy and safety of nivolumab in combination with abemaciclib and ET (LET or FUL) in patients with HR+, HER2- MBC. Since there is no safety data of the combination of nivolumab, abemaciclib and ET, we evaluate safety and tolerability of the combination therapy in the first 6 patients with predefined dose-limiting toxicities. Patients will receive nivolumab 240 mg/body on day 1, 15, abemaciclib 150mg twice daily, and either LET 2.5mg once daily (LET cohort) or FUL 500mg on day1, day15 (FUL cohort) every 4 weeks until disease progression, unacceptable toxicity, or patient refusal. Pre- or perimenopausal women must receive concomitant treatment with a gonadotropin-releasing hormone agonist. Eligibility Criteria: Key eligibility criteria for the LET cohort are: postmenopausal HR+, HER2- MBC with ECOG PS≤1, measurable disease, no prior systemic therapy. ET in the adjuvant setting is permitted if the patient has a disease-free interval &gt; 12 months from the completion of ET. Key eligibility criteria for the FUL cohort are: HR+, HER2- MBC with ECOG PS≤1, measurable disease, no more than one ET or any prior chemotherapy for MBC. Patients are required to have a disease that progressed while receiving adjuvant ET, ≤ 12 months after adjuvant ET, or while receiving ET for MBC. Specific Aims: The primary endpoint is the objective response rate (ORR) and key secondary endpoints include progression-free survival, overall survival, and the safety of the protocol treatment. Statistical Design: The threshold and expected ORR of LET cohort are 55% and 75%, respectively, and 16 patients are needed to ensure a statistical power of 80% (α=0.20). The threshold and expected ORR of FUL cohort are 45% and 60%, respectively, and 32 patients are needed to ensure a statistical power of 80% (α=0.20). Target Accrual: A total of 53 patients (LET cohort: 18, FUL cohort: 35) will be enrolled and duration of enrollment will be 1 year and 4 months. This trial opened to accrual in June 2019. Clinical trial information: JapicCTI-194782. Contact Information: Jun Masuda, Toranomon Hospital, Tokyo, Japan, masu-j@toranomon.gr.jp Citation Format: Jun Masuda, Junji Tsurutani, Norikazu Masuda, Manabu Futamura, Koji Matsumoto, Kenjiro Aogi, Masato Takahashi, Hiroji Iwata, Tsutomu Iwasa, Toru Mukohara, Kenichi Yoshimura, Takayuki Ueno, Toshimi Takano. Phase II study of nivolumab in combination with abemaciclib plus endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer (WJOG11418B, NEWFLAME trial) [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr OT2-04-07." @default.
• W3013765366 created "2020-04-03" @default.
• W3013765366 creator A5008549101 @default.
• W3013765366 creator A5008946028 @default.
• W3013765366 creator A5011017659 @default.
• W3013765366 creator A5012322249 @default.
• W3013765366 creator A5030591160 @default.
• W3013765366 creator A5041726660 @default.
• W3013765366 creator A5044214575 @default.
• W3013765366 creator A5057467660 @default.
• W3013765366 creator A5061220478 @default.
• W3013765366 creator A5067189124 @default.
• W3013765366 creator A5067561532 @default.
• W3013765366 creator A5072348132 @default.
• W3013765366 creator A5081166185 @default.
• W3013765366 date "2020-02-15" @default.
• W3013765366 modified "2023-09-26" @default.
• W3013765366 title "Abstract OT2-04-07: Phase II study of nivolumab in combination with abemaciclib plus endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer (WJOG11418B, NEWFLAME trial)" @default.
• W3013765366 doi "https://doi.org/10.1158/1538-7445.sabcs19-ot2-04-07" @default.
• W3013765366 hasPublicationYear "2020" @default.
• W3013765366 type Work @default.
• W3013765366 sameAs 3013765366 @default.
• W3013765366 citedByCount "3" @default.
• W3013765366 countsByYear W30137653662021 @default.
• W3013765366 countsByYear W30137653662022 @default.
• W3013765366 crossrefType "journal-article" @default.
• W3013765366 hasAuthorship W3013765366A5008549101 @default.
• W3013765366 hasAuthorship W3013765366A5008946028 @default.
• W3013765366 hasAuthorship W3013765366A5011017659 @default.
• W3013765366 hasAuthorship W3013765366A5012322249 @default.
• W3013765366 hasAuthorship W3013765366A5030591160 @default.
• W3013765366 hasAuthorship W3013765366A5041726660 @default.
• W3013765366 hasAuthorship W3013765366A5044214575 @default.
• W3013765366 hasAuthorship W3013765366A5057467660 @default.
• W3013765366 hasAuthorship W3013765366A5061220478 @default.
• W3013765366 hasAuthorship W3013765366A5067189124 @default.
• W3013765366 hasAuthorship W3013765366A5067561532 @default.
• W3013765366 hasAuthorship W3013765366A5072348132 @default.
• W3013765366 hasAuthorship W3013765366A5081166185 @default.
• W3013765366 hasConcept C121608353 @default.
• W3013765366 hasConcept C126322002 @default.
• W3013765366 hasConcept C143998085 @default.
• W3013765366 hasConcept C197934379 @default.
• W3013765366 hasConcept C2775930923 @default.
• W3013765366 hasConcept C2776999253 @default.
• W3013765366 hasConcept C2777176818 @default.
• W3013765366 hasConcept C2777701055 @default.
• W3013765366 hasConcept C2778375690 @default.
• W3013765366 hasConcept C2778812593 @default.
• W3013765366 hasConcept C2780030458 @default.
• W3013765366 hasConcept C2780482068 @default.
• W3013765366 hasConcept C530470458 @default.
• W3013765366 hasConcept C71924100 @default.
• W3013765366 hasConceptScore W3013765366C121608353 @default.
• W3013765366 hasConceptScore W3013765366C126322002 @default.
• W3013765366 hasConceptScore W3013765366C143998085 @default.
• W3013765366 hasConceptScore W3013765366C197934379 @default.
• W3013765366 hasConceptScore W3013765366C2775930923 @default.
• W3013765366 hasConceptScore W3013765366C2776999253 @default.
• W3013765366 hasConceptScore W3013765366C2777176818 @default.
• W3013765366 hasConceptScore W3013765366C2777701055 @default.
• W3013765366 hasConceptScore W3013765366C2778375690 @default.
• W3013765366 hasConceptScore W3013765366C2778812593 @default.
• W3013765366 hasConceptScore W3013765366C2780030458 @default.
• W3013765366 hasConceptScore W3013765366C2780482068 @default.
• W3013765366 hasConceptScore W3013765366C530470458 @default.
• W3013765366 hasConceptScore W3013765366C71924100 @default.
• W3013765366 hasIssue "4_Supplement" @default.
• W3013765366 hasLocation W30137653661 @default.
• W3013765366 hasOpenAccess W3013765366 @default.
• W3013765366 hasPrimaryLocation W30137653661 @default.
• W3013765366 hasRelatedWork W2100085165 @default.
• W3013765366 hasRelatedWork W2690569173 @default.
• W3013765366 hasRelatedWork W2747078758 @default.
• W3013765366 hasRelatedWork W2751810360 @default.
• W3013765366 hasRelatedWork W3013083585 @default.
• W3013765366 hasRelatedWork W3013765366 @default.
• W3013765366 hasRelatedWork W3136162983 @default.
• W3013765366 hasRelatedWork W4226356606 @default.
• W3013765366 hasRelatedWork W4243951155 @default.
• W3013765366 hasRelatedWork W4282924254 @default.
• W3013765366 hasVolume "80" @default.
• W3013765366 isParatext "false" @default.
• W3013765366 isRetracted "false" @default.
• W3013765366 magId "3013765366" @default.
• W3013765366 workType "article" @default.